Infectious Diseases, Tan Tock Seng Hospital
National Centre for Infectious Diseases
Professor David Lye Chien Boon (MBBS, FRACP, FAMS, FRCP) is a Senior Consultant Infectious Diseases Physician at the National Centre for Infectious Diseases and Tan Tock Seng Hospital.
Professor Lye graduated in medicine on the Dean's List from the University of Melbourne in 1996 and completed speciality training in infectious diseases in Australia in 2004. He returned to Singapore to work at the Department of Infectious Diseases, Tan Tock Seng Hospital (TTSH) in 2005.
Professor Lye is a professor at the Lee Kong Chian School of Medicine and Yong Loo Lin School of Medicine, and deputy executive director at Programme for Research in Epidemic Preparedness and Response (PREPARE), Singapore. At TTSH, he founded and led the Antimicrobial Stewardship Programme from 2009 to 2018. At NCID, he headed Singapore Infectious Disease Clinical Research Network (SCRN) from 2014 to 2020, Training and Education Office from 2018 to 2020, NCID Infectious Disease Research and Training Office from 2020 to 2025.
He has been the chair of the National Antimicrobial Stewardship Expert Panel since 2014. He is a member of National Antimicrobial Resistance Control Committee, One Health Antimicrobial Resistance Project Team and Expert Committee on COVID-19 Vaccination, Ministry of Health, Singapore.
To date, Professor Lye has held more than SGD$13 million in research grants as the principal investigator. His research interests are in COVID-19, dengue and antimicrobial resistance. He has published more than 350 peer-reviewed manuscripts in journals such as NEJM, Lancet, JAMA, JAMA Oncology, Lancet Respiratory Medicine, Lancet Infectious Diseases, Lancet Microbe, Lancet Global Health, Annals Internal Medicine as well as Science, Nature Biotechnology, Nature Reviews Immunology, Nature Microbiology, Nature Communications, Science Translational Medicine, Journal Clinical Investigation and Journal Experimental Medicine. He was a Clarivate Highly Cited Researcher 2022.
He is a member of the Editorial Advisory Board, Journal Global Antimicrobial Resistance. He was formerly an associate editor, BMC Infectious Diseases and Scientific Reports, and a member of the editorial board, JAC-Antimicrobial Resistance.
Professor Lye is President of Society of Infectious Disease (Singapore). He is an advocate for HIV prevention as Vice President of Action for AIDS. Internationally, he is President of Asia Pacific Society of Clinical Microbiology and Infection, and an ex officio of executive committee, International Society of Antimicrobial Chemotherapy, and council of International Society of Infectious Diseases.
Professor Lye's awards include: Dean's Award for Teaching Excellence, Yong Loo Lin School of Medicine, 2016; Fellow, International Society of Antimicrobial Chemotherapy, 2020; National Clinical Excellence Team Award, Ministry of Health, 2021; Dean's Award for Research, Lee Kong Chian School of Medicine, 2021; National Healthcare Group Distinguished Achievement Award, 2022; National Healthcare Group Lee Kong Chian Medicine Clinician/Clinical Scientist Award 2022; Public Administration Award (Silver) (COVID-19).
Publications
1. Remdesivir for the Treatment of Covid-19 - Final Report.
2. Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study
3. Developments in pneumonia and priorities for research.
4. Feasibility of wastewater-based detection of emergent pandemics through a global network of airports.
5. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
6. mRNA SARS-CoV-2 Vaccination Before vs During Pregnancy and Omicron Infection Among Infants.
7. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection
8. Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial.
9. Early oral antibiotic switch in Staphylococcus aureus bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol.
10. Empowerment of nurses in antibiotic stewardship: a social ecological qualitative analysis
11. WHO global research priorities for antimicrobial resistance in human health.
12. Evaluation of the Effectiveness of Surveillance and Containment Measures for the First 100 Patients with COVID-19 in Singapore - January 2-February 29, 2020.
13. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.
14. 557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients
15. 548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19
16. 73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir
17. Baricitinib plus Remdesivir for hospitalized adults with Covid-19
18. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
19. Neurology of COVID-19 in Singapore.
20. Hospital Pharmacists and Antimicrobial Stewardship: A Qualitative Analysis
21. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial
22. Contemporary narrative review of treatment options for COVID-19.
23. A vaccination update for rheumatologists-SARS-CoV-2, influenza and herpes zoster.
24. Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality.
25. Remdesivir for the prevention of invasive mechanical ventilation or death in COVID-19 - A post-hoc analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data.
26. Remdesivir for severe coronavirus disease 2019 (COVID-19) versus a cohort receiving standard of care
27. Corrigendum to 'Neurology of COVID-19 in Singapore' [Journal of the Neurological Sciences Volume 418, 15 November 2020, 117118].
28. Effectiveness of a Fourth Dose of COVID-19 mRNA Vaccine Against Omicron Variant Among Elderly People in Singapore.
29. The Staphylococcus aureus Network Adaptive Platform Trial protocol: New tools for an old foe.
30. Prevalence and functional profile of SARS-CoV-2 T cells in asymptomatic Kenyan adults.
31. A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.
32. Multi-dimensional epidemiology and informatics data on COVID-19 wave at the end of zero COVID policy in China.
33. Does adjunctive clindamycin have a role in Staphylococcus aureus bacteremia? A protocol for the adjunctive treatment domain of the S. aureus Network Adaptive Platform (SNAP) randomized controlled trial
34. Win ratio analyses of piperacillin-tazobactam versus meropenem for ceftriaxone non-susceptible Escherichia coli or Klebsiella pneumoniae bloodstream infections: Post-hoc insights from the MERINO trial.
35. Whole-of-Life Inclusion in Bayesian Adaptive Platform Clinical Trials
